November 2016. Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces it has entered into a strategic alliance with Orchard Therapeutics (“Orchard”), a biotechnology company dedicated to bringing transformative ex-vivo stem cell based gene therapies to patients with serious and life-threatening orphan diseases. As part of the agreement the Group will develop and supply lentiviral vectors used by Orchard for the manufacture of ex-vivo gene therapy products in primary immune deficiency disorders and inherited metabolic disorders, including adenosine deaminase severe combined immunodeficiency (ADA-SCID), Mucopolysaccharidosis-IIIA (MPS-IIIA or Xxxxxxxxxx Syndrome type A) and undisclosed follow-on indications. Orchard will lead the global clinical development and commercialisation of collaboration programs in Europe, the United States and in other regions. Under the terms of the collaboration and licence agreement, Oxford BioMedica will receive a 1.95% equity stake in Orchard and will be entitled to royalties on future sales of products covered by the collaboration. The Group will provide process development services and manufacture clinical and commercial GMP-grade lentiviral vectors for Orchard. The process development arrangements include performance-related incentives through which Oxford BioMedica could receive a further 1.95% equity stake in Orchard. The Group has also granted an exclusive intellectual property licence to Orchard for collaboration programmes. Xxxx Xxxxxx, Chief Executive Officer of Oxford BioMedica, commented: “We are delighted to initiate a Strategic Alliance with Orchard Therapeutics and look forward to working with them to develop and launch much needed treatments for patients in desperate need of better treatment options. The alliance combines Oxford BioMedica’s world-leading capabilities in lentiviral vector process development and bioprocessing expertise with Orchard’s expertise in the development and commercialisation of gene therapies for orphan diseases. This further demonstrates Oxford BioMedica’s position as a “go to” partner for companies and academic institutions working with lentiviral vector based products.”
November 2016. The UCDP GED data lists two battle-related FARC deaths on this day. This was shortly before the two sides signed the revised peace agreement. The circumstances surrounding this event are contested. FARC chief negotiator Xxxx Xxxxxxx claimed that the two were on their way to a demobilization zone, but the army stated that the fighters were 69 km from such a zone and were involved in criminal activities (see Xxxx 2016; ICG 2016c). 117 See chapter six, Within-case congruence test. Appendix Chapter Seven This appendix includes additional graphs and tables for the statistical analysis of chapter seven (Logics of ceasefire design) and discusses the findings of the robustness checks. Survival curves for alternative fatality thresholds With a fatality threshold of 1 battle-related death, almost 70% of cessations of hostilities, 50% of preliminary and 30% of definitive ceasefires are considered terminated after only three months (Figure 27). The dynamics for the fatality threshold of 100 battle-related deaths (Figure 28) are very similar for the threshold of 25 fatalities, but with longer survival times.
Examples of November 2016 in a sentence
SIGNED ON BEHALF OF THE CORPORATION OF THE CITY OF WHITE ROCK: SIGNED ON BEHALF OF THE CANADIAN UNION OF PUBLIC EMPLOYEES, LOCAL 402-01: Xxxxxxx Xxxxxxxxx Xxxx Xxxxxxxx Dated at White Rock, British Columbia, this 25th day of November 2016.
SIGNED ON BEHALF OF THE CORPORATION OF THE CITY OF WHITE ROCK: SIGNED ON BEHALF OF THE CANADIAN UNION OF PUBLIC EMPLOYEES, LOCAL 402-01: Dated at White Rock, British Columbia, this 25th day of November 2016.